key: cord-0716175-35gdeh2o authors: Lee, Dong Seok; Kim, Ji Won; Lee, Kook Lae; Jung, Yong Jin; Kang, Hyoun Woo title: Adverse events following coronavirus disease 2019 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study date: 2022-03-09 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.03.007 sha: 84e8fd88b6a81bc41527099be8e2fb7de263556b doc_id: 716175 cord_uid: 35gdeh2o Objectives : To investigate the clinical characteristics of adverse events following coronavirus disease 2019 (COVID-19) vaccination in patients in South Korea. Design : Data from the Korean Disease Control and Prevention Agency on adverse events from four COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26 to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed. Results : Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 adverse events were reported. Most adverse events occurred after the first dose (80.6%) and within a day (63.2%) following vaccination. Of the adverse events, 95.5% were non-severe cases; however, 4.5% were severe. Most of the mild adverse events showed a similar frequency across all age groups, but major severe adverse events and mortality events increased with age. Conclusions : Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in all four COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted. The World Health Organization (WHO) declared the coronavirus disease 2019 as a global pandemic in March 2020. Currently, six COVID-19 vaccines have been approved by the WHO and administered to control transmission, achieve herd immunity, and reduce disease severity and mortality (Swan et al., 2021) . These vaccines are effective in preventing COVID-19 and generally safe to use with a low incidence of adverse reactions and side effects (Baden et al., 2021) (Klein et al., 2021 ) (Oliver et al., 2021 , Polack et al., 2020 (Folegatti et al., 2020) . Adverse reactions following COVID-19 vaccines are primarily mild and short-lasting, including headache, muscle pain, chills, diarrhea, and pain at the inoculation site. However, serious complications such as neurological events (Cari et al., 2021a) (Goss et al., 2021) , myocarditis , anaphylaxis (Shimabukuro et al., 2021) , vesicolousbullous skin (Coto-Segura et al., 2021) , acute kidney injury (Lebedev et al., 2021) , intravascular thrombosis, and thrombocytopenia (Lebedev et al., 2021) (Cari et al., 2021b ) (Pottegård et al., 2021) may rarely occur. Most mild adverse reactions can be managed through rest, intake of non-alcoholic liquids, and acetaminophen (Prevention). Four COVID-19 vaccines are being used in South Korea: AZD1222 (AstraZeneca), BNT162b2 (Pfizer-BioNTech), JNJ-78436735 (Janssen), and mRNA-1273 (Moderna). In the early vaccination stages, AZD1222 was commonly used. However, the BNT162b2 vaccine began to be more commonly used after serious side effects were reported in the AZD1222 vaccine recipients. Regardless, several adverse reactions and complications are still reported to be associated with the four COVID-19 vaccines, leading to vaccine hesitancy (Turner et al., 2021) . From February 26 to August 21, 2021, a total of 153,183 (0.46%) reported individuals experienced adverse reactions from COVID-19 vaccines in South Korea (Agency). Therefore, the aim of this study was to investigate the clinical characteristics of the adverse reactions experienced by patients following the four COVID-19 vaccinations in South Korea. This was a retrospective observational study during the COVID-19 pandemic in South Korea. Data were collected from February 28 to August 21, 2021. The study protocol was approved by the institutional review board of the Boramae Medical Center in Seoul, Korea (approval number 07-2021-36). Informed consent was waived due to the retrospective nature of the study design. Adverse events were reported as suspected adverse reactions after vaccination against (Administration, May 20, 2013) . The guidelines, written in Korean, describe local and systemic reactions, hematology, electrolytes, etc. The severity is divided into Grades 1, 2, 3, and 4. Grade 1 severity occurs within 48 hours, does not require treatment, and does not affect daily activities. Grade 2 severity includes cases in which normal daily activities can still be performed at more than 50% capacity and minimal medical treatment is required. Grade 3 severity include cases where daily activities are limited to less than 50% capacity and hospitalization is required for treatment. Grade 4 is a life-threatening severity and requires hospitalization due to severe activity limitation. Cases with Grades 1 and 2 severities correspond to nonsevere AEs. Grades 3 and 4 correspond to severe AEs. First, enrolled AE cases were divided into four groups based on severity as follows: (1) mild AE, (2) major severe AE, (3) anaphylactic event, and (4) mortality event. Disease severity was classified based on the guidelines developed by the Korean Food & Drug Administration (Administration, May 20, 2013) . Non-severe AEs such as, dizziness, myalgia, headache, fever, nausea, and indigestion were considered as mild AEs. Most severe AEs were critical complications, such as thrombocytopenic purpura, acute paralysis, and acute cardiovascular injury, and were considered major severe AEs. Anaphylaxis and mortality events and were separately classified ( Figure 1 and Table 1 ). Patients whose deaths were confirmed after COVID-19 vaccination were assigned to the mortality group. Second, enrolled AE cases were grouped according to the vaccine administered and age ranges (12-17, 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, ≥80 years) ( Table 2) . The rate of AE following COVID-19 vaccination in each of the four groups was calculated using the following formula (Cari et al., 2021b) : Rate = (number of adverse events / number of vaccinated people) × 1,000, 000 Descriptive variables are reported as median (range) and categorical variables as frequencies. Statistical analyses were performed using SPSS version 20 (IBM Corp., Armonk, NY, USA). A total of 36.3 million individuals completed their COVID-19 vaccine doses during the study period. Four COVID-19 vaccines were administered. The number of vaccinated people and occurrence of AEs were highest in the AZD1222 and BNT162b2 groups. The frequency of AEs was proportional to the frequency of vaccination (Table 1 ). The AEs classified into the following four groups according to severity had these accumulated number of reports: 146,215 mild AEs (95.5%), 5,776 major severe AEs (3.8%), 703 anaphylactic events (0.5%), and 489 mortality events (0.3%) ( Table 1) . For accurate interpretation, we performed data normalization by dividing the number of adverse events by the number of vaccinations. Data correction method is described below each figure. Figures were constructed based on new data. The incidence of mild AE, major severe AE, anaphylactic events, and mortality events was higher in women than in men (Table 1, Figure 5 ). Most adverse events (80.6%) occurred following the first dose of vaccination. Mild AEs and anaphylactic events were mostly seen within one day. However, for severe AEs and mortality events, the onset of symptoms varied (Table 3 and 5, Figure 2 and 6). Adverse reactions with AZD1222 administration were more common with the first dose than with the second dose ( Figure 6 ). However, adverse reactions in BNT162b2 were more common at the second dose than at the first dose, except for anaphylactic reactions. The primary presenting symptoms were pain-related symptoms (63.5%), myalgia (32.2%), headache (29.4%), gastrointestinal symptoms (25.3%), skin-related symptoms (22.4%), neurologic symptoms (17.6%), and arthritis (1.9%). Most presenting symptoms occurred within a day after vaccine administration (63.2%) (Figure 3 , Table 6 ). In mild AEs, the frequency of allergic reaction, headache, arthritis, fever, local skin response, and cellulitis was higher with AZD1222 than BNT162b2 (Figure 3 , Table 6 ). In severe AEs, the frequency of anosmia, acute kidney injury, acute liver damage, thrombocytopenic purpura, thrombocytopenia, neurological complications, and severe skin reactions were higher in AZD1222 than BNT162b2 (Figure 3 , Table 6 ). The frequency of AEs according to age is shown in Figure 2 and Table 2 . Overall, mild AEs showed a similar frequency across all age groups, but major severe AEs and mortality events increased with age. Anaphylactic events were more frequent in the 18- Comparative studies on BNT162b2 and AZD1222 have been conducted and various vaccine adverse reactions have been revealed. However, these are still limited to Saudi Arabia and Europe (Cari et al., 2021b) (Alghamdi et al., 2021) . Studies conducted in Asian countries are rare. This study on adverse reactions following COVID-19 immunization conducted in South Korea has the advantage of having compared four different brands of COVID-19 vaccines in a large-scale research. In this study, as in recently published papers ( (Shimabukuro et al., 2021) ; (Coto-Segura et al., 2021); (Lebedev et al., 2021) ; (Lebedev et al., 2021) ; (Cari et al., 2021b) ), various adverse reactions were identified. These adverse reactions were classified into four groups according to severity, age, sex, and frequency of inoculation. In the interpretation of results, vaccine comparison of adverse reactions was mainly performed between AZD1222 and BNT162b2. The frequency of AEs was higher in women than in men. In BNT162b2 and mRNA-1273, AEs were higher in the second dose than in the first dose. These findings were similar with other studies (Alhazmi et al., 2021) (Polack et al., 2020) . Overall, mild AEs, such as gastrointestinal symptoms, allergic reactions, fever, headache, and myalgia were less frequent in those receiving BNT162b2 and mRNA-1273 than in those receiving AZD1222. Overall, major severe AEs were also less frequent in those receiving BNT162b2 than in those receiving AZD1222. Thrombocytopenic thrombosis occurred with all four vaccines; however, the incidence was lower in those receiving BNT162b2 than in those receiving AZD1222 (Table 6) . Acute cardiac injury such as myocarditis were also less in those receiving BNT162b2 than AZD1222 (Cari et al., 2021a) . Neurologic adverse events such as Guillain-Barré syndrome had a high incidence in those who received AZD1222 than BNT162b2 (Patone Martina et al., 2021) , (García-Grimshaw et al., 2021a) , (García-Grimshaw et al., 2021b) . Our findings were similar with previous studies (Pottegård et al., 2021) (Lau and Galea, 2021) . However, since these AEs may be related to patient factors such as the patient's age, drug susceptibility, genetics, ethnicity, and underlying disease, further investigations are needed to confirm the association. Exacerbation of underlying diseases is often observed in vaccinated individuals ( Table 6 ). The mortality events following vaccination may be attributed to the exacerbation of underlying diseases, particularly in the case of the elderly. Because of this, we believe that the mortality incidence in older age is higher in vaccinated people than in the general population. Adverse reactions observed in vaccinated individuals were very similar to complications in COVID-19 patients. These complications have been described as "Vaccine-Induced COVID-19 Mimicry" Syndrome, a condition caused by COVID-19 vaccines (Kowarz et al., 2021) . However, compared to patients with COVID-19 (Stokes et al., 2020) , vaccinated individuals had a faster onset of symptoms, higher rate of asymptomatic infections, and lower severity and mortality (Swan et al., 2021) . This study had several strengths. First, all adverse reactions in South Korea were objectively collected and processed through an adverse reaction reporting system established by medical and government institutions. Second, data were accumulated weekly for 25 weeks. This large-scale study data helped to improve the reliability of the interpretation of the results. This study had some limitations. First, AEs were reported as suspected adverse reactions after vaccination against COVID-19 and were calculated based on the reports by medical institutions. Patients who did not report AEs were inadvertently excluded from the evaluation. Therefore, actual AEs may have a higher incidence. Second, because blood test data, which could help predict the severity of adverse events, were not available, we could not assess whether vaccinated individuals had elevated levels of inflammation, coagulation, lymphopenia, neutropenia, and troponin, which are hallmark events involved in disease severity. Third, complete causality between the vaccine and the adverse reaction were not secured, and the classification of notification status may change when new information is added. In this study, adverse reactions ranging from mild, severe, and even death were shown in all four COVID-19 vaccines in South Korea. Adverse reactions varied with severity, age, sex, and dose order. Overall AEs were less frequent in those receiving BNT162b2 than in those receiving AZD1222. Caution is needed regarding adverse reactions following COVID-19 vaccination, and further research should be continuously conducted. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Centers for Disease Control and Prevention. Different COVID-19 Vaccines Guidance for Adverse Event Grading Scale for Volunteers in Preventive Vaccine Cl inical Trials Adverse reactions after covid-19 vaccination in Korea ARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees Evaluation of Side Effects As sociated with COVID-19 Vaccines in Saudi Arabia Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Cardiovascular, neurological, and p ulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vac cines: An analysis of European data Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of fo ur cases and review of the literature Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far? Safety and immunoge nicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singl e-blind, randomised controlled trial Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine ANA investigates: neurological complications of COVID-19 vaccines Surveillance for Adverse Events After COVID-19 mRNA Vaccination Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protei n variants that may cause thromboembolic events in patients immunized with vector-based vaccines Risk-benefit analysis of COVID-19 vaccines -a neurological perspective Minimal change disease following the Pfizer-BioNTech COVID-19 Vaccine The Advisory Committ ee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine -Unite d States Neurological complications aft er first dose of COVID-19 vaccines and SARS-CoV-2 infection Risks of myocarditis, p ericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection Safety and efficacy of the BN T162b2 mRNA Covid-19 vaccine Arterial events, venous thromboe mbolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in De nmark and Norway: population based cohort study Selected Adverse Events Reported after COVID-19 Vaccination Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines i n the US Coronavirus Disea se 2019 Case Surveillance -United States COVID-19 vaccines that reduce sy mptoms but do not block infection need higher coverage and faster rollout to achieve population impact